sur VALBIOTIS (EPA:ALVAL)
Valbiotis announces its financial results and strategic progress for 2023
Valbiotis, a company specializing in food supplements to combat metabolic disorders, has published its 2023 annual results, showing a solid cash position of more than 25 million euros. The year was marked by the success of the Phase II/III clinical study on TOTUM•63, for the treatment of prediabetes and type 2 diabetes, and by the industrial and commercial structuring anticipating the first commercializations. The launch of Valbiotis®PRO Cholesterol is planned for May 2024, signifying the company's first revenues.
The company also launched the latest clinical phase for Lipidrive® (formerly TOTUM•070), aimed at reducing high LDL cholesterol. At the same time, the positive results of TOTUM•854 underline its effectiveness in reducing blood pressure. These initiatives support Valbiotis' ambitions to position itself as a key player in the field of natural solutions for metabolic health.
R. E.Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés. Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de VALBIOTIS